Compare BridgeBio Pharma Inc (BBIO) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Wheaton Precious Metals Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Wheaton Precious Metals Corp trades at $135.86 (market cap $60.46B). The key difference: Wheaton Precious Metals Corp is far larger — about 3.6× BridgeBio Pharma Inc's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | WPM | |
|---|---|---|
Market Cap | $16.61B | $60.46B |
Sector | Health | Basic Materials |
52-Week High | $90.17 | $165.72 |
52-Week Low | $47.29 | $91.02 |
Enterprise Value | $18.16B | $62.34B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Wheaton Precious Metals (WPM) trades at $134.20, up 7.1% in 24 hours, near its pivot point of $134. The stock shows strong momentum with bullish moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations with EPS of $1.19 versus $1.15 estimated, driven by higher metal prices and sales volumes. Revenue surged to $2.31 billion in 2025, with net income margins exceeding 64%, while valuation ratios like P/E of 29.77 reflect premium pricing. Analysts maintain an 80% buy rating with a $161.75 consensus target.
Outlook remains positive due to robust cash flow growth and exposure to rising gold/silver prices, but risks include commodity volatility and high valuations. Institutional buying supports upside, though technical indicators suggest near-term consolidation may occur before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
